M&A Deal Summary

Pasithea Acquires AlloMek Therapeutics

On October 12, 2022, Pasithea acquired life science company AlloMek Therapeutics

Acquisition Highlights
  • This is Pasithea’s 2nd transaction in the Life Science sector.
  • This is Pasithea’s 2nd transaction in the United States.
  • This is Pasithea’s 1st transaction in Connecticut.

M&A Deal Summary
Date 2022-10-12
Target AlloMek Therapeutics
Sector Life Science
Buyer(s) Pasithea
Deal Type Add-on Acquisition

Target

AlloMek Therapeutics

Woodbridge, Connecticut, United States
AlloMek Therapeutics is a biotechnology company that provides CIP-137401, a potential macrocyclic mitogen-activated protein kinase kinase 1/2 (MEK) inhibitor for use in a range of CNS-related indications, including neurofibromatosis type 1 (NF1) and Noonan syndrome, as well as potential synergy with its existing multiple sclerosis (MS) development program. AlloMek Therapeutics is based in Woodbridge, Connecticut.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Pasithea

Miami Beach, Florida, United States
Category Company
Founded 2020
Sector Life Science
Employees8
DESCRIPTION

Pasithea is a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders. Pasithea was founded in 2020 and is based in Miami Beach, Florida.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 2 of 2
State (Connecticut) 1 of 1
Country (United States) 2 of 2
Year (2022) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-06-22 Alpha-5 Integrin

Charlottesville, Virginia, United States

Alpha-5 Integrin is a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for the treatment of amyotrophic lateral sclerosis and other neuroinflammatory disorders, such as Multiple Sclerosis. Alpha-5 Integrin is based in Charlottesville, Virginia.

Buy $4M
Mergr

Product

Company

Legal